Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors

Trial Profile

Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs MEDI 3617 (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors MedImmune
  • Most Recent Events

    • 20 Mar 2018 Results (n=116) assessinf tolerability and pharmacokinetics of MEDI 3617 in subjects with advanced solid tumours, refractory to standard therapy as monotherapy and in combination with bevacizumab, carboplatin and paclitaxel, were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 10 Jun 2017 Biomarkers information updated
    • 03 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top